Acute effects of interleukin-6 infusion on apo-B-containing lipoprotein subclasses in humans

References

• Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994;5:207–15.
   PubMedGoogle Scholar
• Hudgins LC, Parker TS, Levine DM, Gordon BR, Saal SD, Jiang XC, Seidman CE, Tremaroli JD, Lai J, Rubin A. A single intravenous dose of endotoxin rapidly alters serum lipoproteins and lipid transfer proteins in normal volunteers. J Lipid Res 2003;44:1489–98.
   PubMed Web of Science ®Google Scholar
• Feingold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes 1992;41(Suppl. 2):97–101.
   PubMed Web of Science ®Google Scholar
• Nonogaki K, Fuller GM, Guentes NL, Moser AH, Staprans I, Grunfeld C, Feingold KR. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995;136: 2143–2149.
   PubMed Web of Science ®Google Scholar
• Lippel K, Gianturco S, Fogelman A, Nestel P, Grundy SM, Fisher W, Chait A, Albers J, Roheim PS. Lipoprotein Heterogeneity Workshop. Arteriosclerosis 1987;7:315–23.
   Google Scholar
• Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families. Prog Lipid Res 1991;30:105–38.
   PubMed Web of Science ®Google Scholar
• Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169–96.
   PubMed Web of Science ®Google Scholar
• Van Hall G, Steensberg A, Sacchett M, Fischer C, Keller C, Schjerling P, Hiscock N, Moller K, Saltin B, Febbraio MA, Pedersen BK. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J. Clin Endocrinol Metab 2003;88: 3005–10.
   Google Scholar
• Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 1999;515:287–91.
   PubMed Web of Science ®Google Scholar
• Warnick GR, Nguyen T, Albers JJ. Comparison of improved precipitation methods for cholesterol quantitation of high density lipoprotein. Clin Chem 1985;31:217–22.
   PubMed Web of Science ®Google Scholar
• Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002;61:201–18.
   Web of Science ®Google Scholar
• Li L, Thompson A, Kitchens RL. Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J Lipid Res 2008;49:1782–93.
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340: 448–54.
   PubMed Web of Science ®Google Scholar
• Chenaud C, Merlani PG, Roux-Lombard P, Burger D, Harbarth S, Luyasu S, Graf J-D, Dayer J-M, Ricou B. Low apolipoprotein A-I at intensive care unit admission and systemic response syndrome exacerbation. Crit Care Med 2004;32: 632–7.
   PubMed Web of Science ®Google Scholar
• Khovidhunkit W, Memon RA, Feingold KR, Grunfeld C. Infection and inflammation-induced proathergenic changes of lipoproteins. J Infect Dis 2000;181(Suppl. 3):S462–72.
   PubMedGoogle Scholar
• Alaupovic P, Knight-Gibson C, Wang C-S, Downs D, Koren E, Brewer JR HB, Gregg RE. Isolation and characterization of an apoA-II-containing lipoprotein (LP-A-II:B complex) from plasma very low density lipoproteins of patients with Tangier disease and Type V hyperlipoproteinemia. J Lipid Res 1991;32:9–19.
   PubMed Web of Science ®Google Scholar
• Stouthard HML, Romijn JA, Van der Pol T, Ender E, Klein S, Bakker PJM, Veenhof CHN, Sauerwein HP. Endocrinologic and metabolic effects of interleukin-6 in humans. Am J Physiol 1995;268:E813–19.
   PubMed Web of Science ®Google Scholar
• Alaupovic P. The significance of apolipoproteins for structure, function and classification of plasma lipoprotein. In: Bradley WA, Gianturco SH, Segrest JP, Methods in enzymology. San Diego, CA: Academic Press, 1996. pp. 32–60.
   Google Scholar
• Berbee JF, Havekes LM, Rensen PC. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 2005;30:97–103.
   Google Scholar
• Berbee JF, van der Hoogt CC, Kleemann R, Schippers EF, Kitchens RL, van Dissel JT, Bakker-Woudenberg IA, Havekes LM, Rensen PC. Apolipoprotein CI stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis. FASEB J 2006;20:2162–4.
   PubMed Web of Science ®Google Scholar
• Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas F, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006;113:691–700.
   PubMed Web of Science ®Google Scholar
• Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas F, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006;114:681–7.
   PubMed Web of Science ®Google Scholar
• Lee JS, Campos H, Lemuel M, Sacks FM. LDL-containing apolipoprotein C-III is an independent risk factor for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003;23:853–8.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. VLDL Apolipoproteins B, C-III and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation 2000;102:1886–92.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Rall Jr SC Apolipoprotein E: far more than a lipid transport protein. Annu Rev Hum Genet 2000;1: 507–37.
   Google Scholar
• Flegel WA, Baumstark MW, Weinstock C, Berg A, Northoff H. Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun 1993;61:5140–6.
   PubMed Web of Science ®Google Scholar
• Barcia AM, Harris HN. Triglyceride-rich lipoproteins as agents of immunity. Clin Infect Dis 2005;41:S498–503.
   PubMed Web of Science ®Google Scholar
• Grunfeld C, Feingold KR. HDL and innate immunity: a tale of two apolipoproteins. J Lipid Res 2008;49:1605–6.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Weisgraber KH, Huang Y. Inaugural article. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5644–51.
   PubMed Web of Science ®Google Scholar
• Laskowitz DT, Lee DM, Schmechel D, Staats HF. Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 2000;41:613–20.
   PubMed Web of Science ®Google Scholar
• Ali K, Middleton M, Pure E, Rader DJ. Apolipoprotein E suppresses the type 1 inflammatory response in vivo. Circ Res 2005;97:922–7.
   PubMed Web of Science ®Google Scholar
• Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E- deficient mice. J Immunol 2004;173: 6366–75.
   PubMed Web of Science ®Google Scholar
• Moretti EW, Morris RW, Podgoreanu M, Schwinn DA, Newman MF, Bennett E, Moulin VG, Mba UU, Laskowitz DT. Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team. ApoE polymorphism is associated with risk of severe sepsis in surgical patients. Crit Care Med 2005;33:2521–6.
   PubMed Web of Science ®Google Scholar
• deBont N, Netea MG, Demacker PN, van der Meer JW, Stalenhoef AF. Apolipoprotein-E deficient mice exhibit an increased susceptibility to Klebsiella pneumonia infection. J Lipid Res 1999;40:680–5.
   PubMed Web of Science ®Google Scholar
• van Oosten M, Rensen PCN, Van Amersfoort ES, Van Eck M, Van Dam AM, Breve JJP, Panet A, Van Berkel TJC, Kuiper J. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. J Biol Chem 2001;276:8820–4.
   PubMed Web of Science ®Google Scholar
• Rensen PCN, Jong MC, van Vark LC, van der Boom H, Hendriks WL, Van Berke TJC, Biessen EAL, Havekes LM. Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo: evidence for retroendocytosis. J Biol Chem 2000;275:8564–71.
   PubMed Web of Science ®Google Scholar
• Jahangiri A, deBeer MC, Nofsinger V, Tannock LR, Ramaiah G, Webb NR, van der Westhuysen DR, deBeer FC. HDL remodeling during the acute phase. Arterioscler Thromb Vasc Biol 2009;29:261–7.
   PubMed Web of Science ®Google Scholar
• Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation 2010:1722–34.
   PubMed Web of Science ®Google Scholar